Drug Trial Radar · NCT00420212
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jan 26, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,234
Actual
Start
Jan 2007
Primary completion
Feb 2011
Study completion Feb 2011
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jan 11, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse. The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects RelapsedTime frame: 2 years
Locations
159 sites in 29 countries. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona
Research Site
Phoenix, Arizona
Research Site
San Francisco, California
Research Site
New Haven, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Vero Beach, Florida
Research Site
Atlanta, Georgia
Research Site
Evanston, Illinois
Research Site
Palos Heights, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Indianapolis, Indiana
Research Site
Des Moines, Iowa
Research Site
Wichita, Kansas
Research Site
Lexington, Kentucky
Research Site
Brighton, Massachusetts
Research Site
Hopedale, Massachusetts
Research Site
Lexington, Massachusetts
Research Site
Springfield, Massachusetts
Research Site
Worcester, Massachusetts
Research Site
Farmington Hills, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Columbia, Missouri
Research Site
St Louis, Missouri
Research Site
Henderson, Nevada
Research Site
Las Vegas, Nevada
Research Site
Lebanon, New Hampshire
Research Site
Albany, New York
Research Site
Staten Island, New York
Research Site
Raleigh, North Carolina
Research Site
Dayton, Ohio
Research Site
Erie, Pennsylvania
Research Site
Hershey, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
East Providence, Rhode Island
Research Site
Providence, Rhode Island
Research Site
San Antonio, Texas
Research Site
Newport News, Virginia
Research Site
Wien, Virginia
Research Site
Seattle, Washington
Research Site
Fitzroy, Australia
Showing 40 of 159 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.